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Abstract  
Software is becoming an increasingly important aspect of medical devices and medical 
device regulation. Software enables highly complex systems to be built. However, 
complexity is the enemy of safety, therefore strict adherence to well documented 
processes is important within the domain of medical device software. Medical devices 
can only be marketed if compliance and approval from the appropriate regulatory 
bodies (e.g. the Food and Drug Administration (FDA)) is achieved. This paper outlines 
the development of a software process improvement (SPI) model specifically for the 
medical device industry. The paper details how medical device regulations may be 
satisfied by extending relevant practices from Automotive SPICE. 
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1 Introduction 
Medical device companies must produce a design history file detailing the software 
components and processes undertaken in the development of their medical devices. 
Due to the safety-critical nature of medical device software it is important that highly 
efficient software development practices are in place within medical device companies. 
The risk of patient injury from software defects is a concern due to the manufacture 
and deployment of increasing numbers of software-embedded medical devices. There 
have been a number of major medical device product recalls over this past 25 years 
that were the result of software defects [1]. For example, four people died and two 
were left permanently disfigured from massive radiation overdoses due to software 
defects in the Therac-25 line of medical linear accelerators [2]. A major contributor to 
the defects of such faults is the presence of software quality assurance issues [3]. The 
Center for Devices and Radiological Health (CDRH) reviewed medical device recalls 
due to software failures between 1983 to 1991 and estimated that 90% were due to 
inadequate design and 19% were caused by inadequate change contol [4]. It is 
therefore important that a medical device company has efficient software design and 
quality assurance procedures in place.  
 
2 SPI within safety-critical domains 
Previous research has investigated the suitability of using existing software quality 
assurance standards in order to achieve FDA [5,6,7,8 ] compliance related to the 
areas of process management, requirements specification, design control and change 
control [1]. However, no specific SPI model has been developed for the industry.  
 
If we investigate other regulated industries such as the automotive and space 
industries we realise that these domains are not content with satisfying regulatory 
standards, but have proactively developed SPI models specifically for their domain so 
that they may continuously improve the development of their information systems to 
achieve higher levels of safety, greater efficiency, and a faster time to market, whilst 
seamlessly satisfying regulatory quality requirements. The major SPI models that 
currently exist, namely ISO/IEC15504 [9] and CMMI [10], do not address the 
regulatory requirements of either the medical device, automotive or space industries. 
Therefore, a new SPI model was developed specifically for the automotive industry, 
this model was based upon ISO/IEC15504 and is referred to as Automotive Spice [11]. 
Likewise, a new ISO/IEC15504 based SPI model was developed specifically for the 
space industry, this model is known as SPiCE for SPACE [12]. Both of these models 
contain reference and assessment information in relation to how companies may 
improve their practices within their domain.  
 
This paper investigates how thorough current medical device regulations are in 
relation to specifying what software development practices medical device companies 
should adopt when developing software. This is achieved through comparing current 
medical device regulations and guidelines for software development against the 
formally documented software engineering “best practices” of Automotive SPICE for 
associated process areas.    
 
Additionally, this paper highlights the need for a SPI model within the medical device 
industry (MedeSPI). It describes the development of MedeSPI based upon applicable 
processes from the Automotive SPICE model. The Automotive SPICE model is being 
used as a foundation upon which to develop this model as it has been designed to 
assist with the development of safety-critical software (for the automtive industry) 
which is therefore more applicable to the medical device domain than the generic 
version of ISO/IEC 15504. This paper will also illustrate high-level mappings that have 
been performed between medical device regulations and Automotive SPICE.  
3 The Development of MedeSPI 
The approach for delivering MedeSPI is illustrated in Figure 1. The model is flexible in 
that relevant elements may be adopted to provide the most significant benefit to the 
business.  We describe how MedeSPI has been developed by extending Automotive 
SPICE processes with practices from medical device regulations. 
3. Project outline. 
 
The Software Development Method for Medical Devices (SDMMD) is a defined set of 
software process models which when utilised will meet the goals of MedeSPI. SDMMD 
will cover the complete software development lifecycle. SDMMD will provide a 
software development roadmap, which addresses the regulatory guidance criteria, 
while introducing best practices that can be selected as required.  MedeSPI will 
provide a means of assessing software engineering capability in eleven areas that 
have been defined by the FDA as:   
 
1. Level of Concern 
2. Software Description 
3. Device Hazard and Risk Analysis 
4. Software Requirements Specification 
5. Architecture Design 
6. Design Specifications 
7. Requirements Traceability Analysis 
8. Development 
9. Validation, Verification and Testing  
10. Revision Level History 
11. Unresolved Anomalies 
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Figure 1: Software framework approach 
MedeSPI is being developed to promote SPI practices into the software development 
processes of medical device companies. This is an attempt to improve the 
effectiveness and efficiency of software practices used by medical device companies 
through investigating the mapping between relevant Automotive SPICE processes and 
the eleven FDA areas.  
 
Whilst all Automotive SPICE processes are applicable to the development of safety-
critical medical device software, certain processes are essential in terms of satisfying 
the eleven areas defined by the FDA. Therefore companies must comply with these 
processes in order to market their medical devices. These processes are as follows: 
 
• Risk Management (applicable to FDA area 1 & 3) 
• Requirements Elicitation (applicable to FDA area 4)  
• Software Requirements Analysis (applicable to FDA area 4) 
• Software Design (applicable to FDA area 5 & 6) 
• Software Construction (applicable to FDA area 8) 
• Software Integration test (applicable to FDA area 9) 
• Software Testing (applicable to FDA area 9) 
• System Integration Test (applicable to FDA area 9) 
• System Testing (applicable to FDA area 9) 
• Verification (applicable to FDA area 9) 
• Documentation (applicable to FDA area 2) 
• Configuration Management (applicable to FDA area 10) 
• Problem Resolution Management (applicable to FDA areas 10 & 11) 
• Change Request Management (applicable to FDA area 4 & 7) 
 
The mappings between the FDA regulatory guidelines and the relevant Automotive 
SPICE processes then produce MedeSPI processes that retain the Automotive SPICE 
process names. Like Automotive SPICE, each of the MedeSPI processes consist of a 
purpose, a number of outcomes and a number of base practices that will have to be 
performed in order to fulfil the outcomes. The performance of the base practices 
provides an indication of the extent of achievement of the process purpose and 
process outcomes. Work products are either used, produced or both, when performing 
the process [13]. The composition of the MedeSPI processes is illustrated in figure 2. 
 
 
 
 
 
 
  
 
A- Automotive SPICE  Practices that are not mandatory for FDA compliance. 
B- Automotive SPICE  Practices that are required for FDA compliance. 
C- Non-Automotive SPICE  Practices that are required for FDA compliance. 
 
Figure 2. Composition of MedeSPI processes. 
 
MedeSPI will highlight what additional practices have to be added to the associated  
Automotive SPICE processes in order to satisfy medical device regulations, as well as 
any Automotive SPICE outcomes and associated base practices that are not required 
in order to satisfy medical device regulatory requirements. Due to the scale of the 
entire MedeSPI model this paper will focus upon the process reference model for the 
risk management process as this is a very important process in relation to the 
development of safety-critical software for the medical device industry. 
 
4 MedeSPI Risk Management process 
 
The MedeSPI Risk Management (RM) process seeks to combine the various 
guidelines and standards within the medical device industry.  It does so in the context 
of the following regulations: ISO 14971 [14], SW68 [15], TIR32 [16] and GAMP 4 [17] 
and CDRH (FDA specific) [5, 6, 7] guidance documents. The RM process outlined in 
this paper was developed following an extensive literature review of standards and 
CDRH guidance papers which govern the medical device software industry. The 
primary focus of this research area is to investigate if the medical device regulation for 
RM may be satisfied through adopting the Automotive SPICE RM process. This paper 
describes an integral part of this research by detailing the development of a MedeSPI 
RM process that is based upon the Automotive SPICE RM process. Upon 
development, the MedeSPI RM process will be an extension of the Automotive SPICE 
RM process that is specifically tailored to fulfil the RM regulations of the medical 
device software industry. The RM process may then be adopted by medical device 
companies to improve their software development practices by providing them with a 
SPI based process that will also ensure that their hazard analysis and risk control 
procedures satisfy the current medical device regulations and guidelines. The Failure 
Mode and Effects Analysis (FMEA) method of identifying, mitigating and tracking risk 
and hazard issues will be used within the RM process [18].   
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The next section details a mapping of the medical device standards and guidelines 
(these shall be referred to as medical device regulations throughout the paper) against 
the Automotive SPICE RM process.  
 
4.1 RMCM DEVELOPMENT 
In this section medical device regulations and guidelines, which have a counterpart 
within the goals and practices of the Automotive SPICE RM process area and are 
related to the creation of software are identified.   
 
The purpose of the Automotive SPICE RM process is to identify, analyse, treat and 
monitor the risks continuously. The following outcomes are produced as a result of 
successful implementation of the RM process [13]: 
1) the scope of the risk management to be performed is determined; 
2) appropriate risk management strategies are defined and implemented; 
3) risks are identified as they develop during the conduct of the project; 
4) risks are analysed and the priority in which to apply resources to treatment of these 
risks is determined; 
5) risk measures are defined, applied, and assessed to determine changes in the 
status of risk and the progress of the treatment activities; and 
6) appropriate treatment is taken to correct or avoid the impact of risk based on its 
priority, probability, and consequence or other defined risk threshold. 
NOTE 1: Risks may include technical, economic and timing risks. 
NOTE 2: Risks are normally analysed to determine their probability, consequence and 
severity. 
NOTE 3: Major risks may need to be communicated to and monitored by higher levels 
of management. 
NOTE 4: Different techniques may be used to analyze a system in order to understand 
if risks exist, for example, functional analysis, simulation, FMEA, FTA etc 
 
In the following section the MedeSPI RM process is developed through mapping 
regulatory medical device practices against the seven base practices (BP) specified in 
Automotive SPICE for RM. These are as follows:  
• BP1: Establish risk management scope; 
• BP2: Define risk management strategies; 
• BP3: Identify risks; 
• BP4: Analyse risks; 
• BP5: Define risk treatment actions; 
• BP6: Monitor risks; 
• BP7: Take corrective action.  
4.1.1 BP1: Establish risk management scope  
The aim of this practice is to determine the scope of the RM to be performed. Both 
Automotive SPICE and the medical device regulations specify that the RM scope 
should be defined. Additionally, the medical standards specify that the strategy should 
include the life-cycle phases for which the strategy is applicable (see table 1).  
 
Table 1: MedeSPI RM Sub-Base Practices for Establishing RM scope 
Sub-Practice Specified in 
Automotive SPICE 
Specified in the 
Medical device 
regulations 
Determine the scope of risk management to be performed for 
the project, in accordance with organizational risk management 
policies.  
Yes Yes 
Define the scope of the strategy and include those life-cycle 
phases for which the strategy is applicable  
 No Yes 
 
 
4.1.2 BP2: Define risk management strategies 
The aim of this practice is to define an appropriate RM strategy. Defining a RM 
strategy involves establishing and maintaining a strategy to be used for RM. Both 
Automotive SPICE and the FDA require companies to have a RM strategy that is used 
to define risk analysis and control activities, which should be documented.  However, 
medical device regulations are more stringent in terms of what constitutes a RM 
strategy and therefore additional activities (other than those detailed in Automotive 
SPICE) have to be included within this practice in order to fulfil the objectives of the 
MedeSPI RM process. For example, the FDA guidelines specify that a strategy should 
include: potential sources of risk; appropriate techniques for risk analysis of software, 
electronics, biomaterials etc., such as fault tree analysis, failure modes and effects 
analysis; risk criteria, parameters and thresholds; risk control methods; & activities 
used to monitor the risks and whether risk controls were successful [7]. Table 2, 
demonstrates that 9 additional medical device specific sub-practices have been added 
in order to provide full coverage of the medical device regulations. 
 
Table 2: MedeSPI RM Sub-Base Practices for Defining RM strategies 
 
Sub-Practice Specified in Automotive 
SPICE 
Specified in the Medical 
device regulations 
Define appropriate strategies to identify risks Yes Yes 
Define appropriate strategies to mitigate risks Yes Yes 
Set acceptability levels for each risk or set of risks, both 
at the project and organizational level 
Yes Yes 
Include a verification plan as part of the strategy  No Yes 
Outline the allocation of responsibilities  No Yes 
Outline the requirements for reviewing the RM 
activities  
No Yes 
The RM strategy should include Off-The-Shelf 
Software  
No Yes 
Post-production queries and bugs be should analysed  No Yes 
At least one trained individual directly involved in the 
software development, with both relevant medical 
device and RM knowledge shall participate in the RM 
activity to ensure that risks are adequately addressed.  
This person(s) shall be identified on the report along 
with the date of the analysis 
No Yes 
Determine software hazards  No Yes 
Include failure in the OTS software as a potential 
hazard  
No Yes 
Include hardware failures as a potential hazard No Yes 
 
4.1.3 BP3: Identify risks 
The aim of this practice is to identify risks as they arise during the development and 
maintenance of a software development project. From mapping the medical device 
regulations against Automotive SPICE for this practice, it was discovered that all of 
Automotive SPICE sub-practices are required in order to achieve medical device 
regulatory compliance. However, the medical device regulations request additional 
information in relation to documentation, usage and  traceability. Therefore, an 
additional 3 additional medical device specific sub-practices are required in order to 
achieve the objectives of the MedeSPI RM process (see table 3). 
 
Table 3: MedeSPI RM Sub-Base Practices for Identifying Risks 
Sub-Practice Specified in Automotive 
SPICE 
Specified in the Medical 
device regulations 
Identify risks to the project both initially within the 
project strategy and as they develop during the conduct 
of the project, continuously looking for risk factors at 
any occurrence of technical or managerial decisions. 
Yes Yes 
Identify risks associated with cost, schedule, effort, 
resource and technical areas. 
Yes Yes 
Review environmental elements that may impact the 
project - Risks may include technical, economic and 
timing risks 
Yes Yes 
Document the context, conditions, and potential 
consequences of the risk 
No Yes 
Include a description of the intended use and any 
foreseeable misuse  
No Yes 
Provide risk traceability: Identify risk traceability from 
the device level down to the specific cause within the 
software  
No Yes 
 
4.1.4 BP4: Analyse risks 
The aim of this practice is to analyse risks to determine the priority in which to apply 
resources to the treatment of these risks. From mapping the medical device 
regulations against the Automotive SPICE base practice for analysing risks, it was 
discovered that the medical device regulatory requirements for this practice will be fully 
satisfied through adopting the corresponding Automotive SPICE base practice (see 
table 4). Therefore the MedeSPI base practice for analysing risks will contain 3 sub-
base practices that are applicable to both Automotive SPICE and the medical device 
regulations.   
 
Table 4: MedeSPI RM Sub-Base Practices for Analysing Risks 
 
Sub-Practice Specified in Automotive 
SPICE 
Specified in the Medical 
device regulations 
Evaluate the identified risks using the defined risk 
parameters 
Yes Yes 
Analyse risks to determine their probability, 
consequence and severity. 
Yes Yes 
Prioritise risks for mitigation based upon the 
probability and impact of each identified risk. 
Yes Yes 
 
4.1.5 BP5: Define risk treatment actions 
The aim of this practice is to define actions to correct or avoid the impact of risk. 
Additionally, this practice also seeks to define risk measures to determine changes in 
the status of risk and the progress of risk treatment activities. From mapping the 
medical device regulations against the Automotive SPICE base practice for defining 
risk treatment actions, it was discovered that the medical device regulatory 
requirements for this practice will not be satisfied through adopting the corresponding 
Automotive SPICE base practice (see table 5). In fact, the MedeSPI base practice for 
defining risk treatment actions requires 2 additional sub-practices to be added to the 
Automotive SPICE sub-practices in order to satisfy the medical device regulations. 
Sub-practices had to be added to ensure that resources were committed to risk-
handling activities and that all risk mitigations should be verified. Therefore, the 
MedeSPI RM practice for defining risk treatment actions contains 4 sub-practices – all 
4 are required in order to fulfil regulatory medical device requirements, but only 2 are 
required in order to satisfy Automotive SPICE in relation to this practice.  
 
Table 5: MedeSPI RM Sub-Base Practices for Defining risk treatment actions 
 
Sub-Practice Specified in Automotive 
SPICE 
Specified in the Medical 
device regulations 
Determine the levels and thresholds that define when a 
risk becomes unacceptable and triggers the execution of 
a risk mitigation or contingency plan 
Yes Yes 
Develop mitigation & contingency plans for all risks Yes Yes 
Provide continued commitment of resources for each 
plan to allow successful execution of the risk-handling 
activities 
No Yes 
Mitigations should be verified  No Yes 
 
 
4.1.6 BP6: Monitor risks  
The aim of this practice is to apply and monitor risk metrics to determine changes in 
the status of risks and the progress of risk treatment activities. From mapping the 
medical device regulations against the Automotive SPICE base practice for defining 
risk treatment actions, it was discovered that the medical device regulatory 
requirements for this practice would almost be satisfied through following the sub-
practices of the corresponding Automotive SPICE base practice (see table 6). 
However, the MedeSPI RM base practice for monitoring risks requires an additional 
sub-practice to be added to the Automotive SPICE sub-practices in order to satisfy the 
medical device regulations. A sub-practice had to be added to ensure that the results 
of mitigation verification are verified. Therefore, the MedeSPI RM practices for 
monitoring risks contains 4 sub-practices – all 4 are required in order to fulfil regulatory 
medical device requirements, but only 3 are required in order to satisfy Automotive 
SPICE in relation to this practice.  
 
Table 6: MedeSPI RM Sub-Base Practices for Monitoring risks 
 
Sub-Practice Specified in Automotive 
SPICE 
Specified in the Medical 
device regulations 
Results of the mitigation verification should be 
documented 
No Yes 
Monitor risk status; Yes Yes 
Provide a method for tracking open risk-handling 
options when monitored risks exceed the defined 
thresholds 
Yes Yes 
Collect performance measures on the risk-
handling activities. 
Yes Yes 
 
4.1.7 BP7: Take corrective action 
The aim of this practice is for appropriate treatment to be taken to correct or avoid the 
impact of risks based upon priority, probability, and consequence. Appropriate 
corrective action should be taken when expected progress has not been achieved. 
From mapping the medical device regulations against the Automotive SPICE base 
practice for taking corrective actions, it was discovered that the medical device 
regulatory requirements for this practice would not be satisfied through following the 
sub-practices of the corresponding Automotive SPICE base practice (see table 7). The 
MedeSPI RM base practice for taking corrective action requires an additional sub-
practice to be added to the Automotive SPICE sub-practices in order to satisfy the 
medical device regulations. A sub-practice had to be added to ensure that the results 
of all the RM activities should be recorded and maintained in a RM file mitigation. The 
MedeSPI RM practice for taking corrective action contains 2 sub-practices – both are 
required in order to fulfil regulatory medical device requirements, but only one is 
required in order to satisfy Automotive SPICE in relation to this practice.  
 
 
 
Table 7: MedeSPI RM Sub-Base Practices for Taking corrective action  
Sub-Practice Specified in 
Automotive SPICE 
Specified in the 
Medical device 
regulations 
Invoke selected risk-handling options when monitored 
risks exceed the defined thresholds 
Yes Yes 
The results of all the RM activities should be recorded 
and maintained in a RM file  
No Yes 
 
4.2 Summary of the MedeSPI RM 
Table 8, illustrates that there are 33 sub-practices within MedeSPI RM. Each of these 
sub-practices are required within the medical device industry whereas only 16 are 
required within the Automotive SPICE RM process. Only one of the seven Automotive 
SPICE base practices fully satisfies the requirements of the associated MedeSPI RM 
practice. Therefore, the mappings highlight that MedeSPI needs to be more 
comprehensive in its coverage of the RM process than Automotive SPICE in order to 
satisfy the regulatory requirements of the medical device industry. 
 
Table 8: Summary of MeDeSPI RM 
Practice Automotive 
SPICE Sub-
Practices 
Automotive SPICE Sub-
Practices required to meet 
regulatory medical device 
requirements 
Additional Sub-Practices required 
to meet regulatory medical device 
requirements 
BP1: Establish risk 
management scope 
1 1 1 
BP2: Define risk 
management 
strategies 
3 3 9 
BP3: Identify risks 3 3 3 
BP4: Analyse risks 3 3 0 
BP5: Define risk 
treatment actions 
2 2 2 
BP6: Monitor risks 3 3 1 
BP7: Take 
Corrective action 
1 1 1 
Total 16 16 17 
5 Conclusions 
With respect to the practices of the MedeSPI RM process, it is clear that following the 
base practices of the Automotive SPICE RM process will at best, only partially meet 
the regulatory requirements of the medical device industry in relation to RM. For RM, 
the existing Automotive SPICE specification of outcomes and base practices can be 
carried over, with the extension mentioned above into the MeDeSPI framework. 
 
We are still developing MedeSPI. Our approach is to examine all of the appropriate 
processes that have listed in section 3, and investigate the extent to which the 
Automotive SPICE framework needs to be extended to create MeDeSPI. Our vision is 
to provide a framework that will encourage medical device companies to distance 
themselves from the concept of developing the software first and then completing the 
necessary documentation that is required to achieve FDA compliance, to instead 
pursuing a continuous SPI path that will produce more efficient software development 
and safer medical devices. In this paper we have focused upon RM which is a key 
process within the medical device industry and therefore requires comprehensive 
coverage, however in other processes we may discover that the associated 
Automotive SPICE base practices will more than satisfy the regulatory medical device 
requirements and in these cases the medical device industry may be able to adopt 
some of the additional Automotive SPICE sub-practices to increase the efficiency of 
that process. 
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